Charis Antoniades

Charis Antoniades holds a BHF Chair of Cardiovascular Medicine at the University of Oxford, and he practices as a Consultant Cardiologist at Oxford University Hospitals. He was awarded his PhD title with hons on the genetics of premature myocardial infarction from the University of Athens, and during his PhD studies he won multiple Young Investigator award competitions, including those of the European Society of Cardiology (ESC) twice, American College of Cardiology, ISHR and others. He has been awarded the Outstanding Achievement Award of the basic Cardiovascular Science Council of the European Society of Cardiology in 2016, a National clinical excellence award in 2021 and an N3 National Clinical Impact Award in 2024, while he has given various named lectures. He is the Director, Acute Multidisciplinary Imaging & Interventional Centre, University of Oxford, the Deputy Head of the Division of Cardiovascular Medicine. He also served as the Chair of the British Atherosclerosis Society 2021-2024, while he is involved in several leadership roles within the ESC. In 2024 he was elected Fellow of the Academy of Medical Sciences. His research is focused on the study of the cross-talk between adipose tissue and the cardiovascular system, with specific interest in the non-invasive imaging of inflammation and the use of artificial intelligence (AI) for risk prediction. He directs the Oxford Heart Vessels and Fat programme, and coordinates large national flagship programmes (such as the UK C19-CRC) and international multicentre studies (e.g. ORFAN study). His research has led to the development of novel AI-derived imaging biomarkers using Computed Tomography, with major role in cardiovascular risk prognosis. He is also deputy editor of Cardiovascular Research and serves at several editorial boards, while he is one of the founders of the Scientists of Tomorrow of the ESC. He has published more than 350 peer review scientific papers in high impact journals like the Lancet, Science Transl Med, Circulation, JACC, EHJ and others. Finally, he is founder and Chief Scientific Officer of Caristo Diagnostics, a university of Oxford spinout company.